PACS (PACS Group) Research & Development: $0 Mil (TTM As of Mar. 2026)


PACS PACS Group Inc PACS
19 GF Score
Price $38.85
! 5 Warning Signs
View Full Analysis

What is PACS Group Research & Development?

PACS Group PACS +3.96% 19 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates PACS with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PACS Group's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

PACS Group  (NYSE:PACS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PACS Group Research & Development Related Terms

PACS Group Research & Development Historical Data

* Premium members only.

The historical data trend for PACS Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PACS Group Research & Development Chart

PACS Group Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00 0.00 0.00

PACS Group Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PACS
19GF Score
PACS Group Inc PACS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PACS Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
PACS Group (PACS) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PACS Group and its competitors.
Is PACS Group's Research & Development too high?
PACS Group's current Research & Development is $0 Mil. Overall, PACS Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does PACS Group's Research & Development compare to CHE and OPCH?
PACS Group's Research & Development of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PACS Group and its competitors. PACS Group's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PACS Group stock overvalued right now?
PACS Group (PACS) has a current Research & Development of $0 Mil. The current Research & Development is $0 Mil. PACS Group's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PACS Group (PACS), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PACS Group Business Description

Address 90 S. 400 W, Suite 700, Salt Lake City, UT, USA, 84101
PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after getting discharged from the hospital. It also provides senior care, assisted living, and independent living options in some of the communities. The company has one reportable segment.
19GF Score

Get the complete analysis for PACS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.85
Price